Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD

In a multinational placebo‐controlled phase III clinical trial in 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, treatment with the Nrf2 activator bardoxolone methyl increased estimated glomerular filtration rate, a measure of kidney function, but also resulted in i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, James H., Jadoul, Michel, Block, Geoffrey A., Chin, Melanie P., Ferguson, Deborah A., Goldsberry, Angie, Meyer, Colin J., O’Grady, Megan, Pergola, Pablo E., Reisman, Scott A., Wigley, W. Christian, Chertow, Glenn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877861/
https://www.ncbi.nlm.nih.gov/pubmed/32860734
http://dx.doi.org/10.1111/cts.12868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877861/
https://www.ncbi.nlm.nih.gov/pubmed/32860734
http://dx.doi.org/10.1111/cts.12868

Ejemplares similares